STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
CRSP CRISPR THERAPEUTICS AG StockScouter® Report
4
StockScouter® Score
CRISPR THERAPEUTICS AG, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
- Moving average analysis for CRSP suggests strong price movement over the medium term. Positive
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- Two or more executives, board directors or major shareholders – including one high-level executive -- sold a large number of shares recently. Very negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
C
F
F
B